samedan logo
 
 
spacer
home > white papers > The Promise and Challenge of Adaptive Design in Oncology Trials - Medpace
WHITE PAPERS
logo_Medpace.JPG

Medpace

phone +1.513.579.9911
email info.uk@medpace.com (UK) / info@medpace.com (US)
web http://www.medpace.com
email Medpace 5375 Medpace Way Cincinnati, Ohio 45227

The Promise and Challenge of Adaptive Design in Oncology Trials

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research.

Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.


The Promise and Challenge of Adaptive Design in Oncology Trials
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Gerresheimer introduces metal-free syringe

Düsseldorf/Bünde/Frankfurt, October 24, 2017. Biotechnologically manufactured active ingredients demonstrate a series of special features. Some are highly viscous and in individual cases, tend to interact with silicone oil or, for example, tungsten residue from syringe production. Gerresheimer therefore offers integrated thin-walled cannulas for the improved emptying capability of the syringe for these applications. The special silicone oil treatment for the reduction of free silicone oil (baked-on) and the “metal-free” production without a tungsten pin create a perfect primary packaging material for these sophisticated medications.
More info >>


White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>


Industry Events

Pharmapack Europe 2018

7-8 February 2018, Hall 7.1, Paris Expo, Porte de Versailles, Paris.

As Europe's dedicated Pharmaceutical Packaging and Drug Delivery event, Pharmapack is the industry's go-to place to kick-off the year.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement